Zoerythromycin can obtain good efficacy in symptomatic treatment of acute lymphoblastic leukemia and acute granulocytic leukemia, but it is ineffective in the treatment of other types of leukemia. Zoerythromycin can treat acute granulocytic leukemia, can be used alone or in combination with other antitumor drugs, the product is suitable for the treatment of various stages of the disease, but also for the treatment of early juvenile granulocytic leukemia, but also for the treatment of acute lymphoblastic leukemia. Zoerythromycin is also effective in neuroblastoma and rhabdomyosarcoma. Common adverse reactions to this product include urticaria, contact dermatitis, rash, reversible alopecia, acute nausea and vomiting, abdominal pain, diarrhea, mucositis, scleritis, thrombophlebitis, severe cellulitis, localized tissue necrosis, hyperuricemia, chills, fever, and anaphylactic-like reactions, and serious adverse reactions include cardiotoxicity and bone marrow suppression. This product is contraindicated in patients who are allergic to the active ingredients or excipients of anthracyclines, pregnant and lactating women, persistent myelosuppression, presence of severe infections, severe hepatic or renal impairment, myocardial insufficiency, recent myocardial infarction, severe cardiac arrhythmia, and so on. It is recommended that patients who are not feeling well should go to a regular hospital in time and follow the doctor’s instructions for symptomatic treatment.